SDV2102

SDV2102 is a first-in-class antibody-drug conjugate (ADC) developed by Syndivia for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It targets the prostate-specific membrane antigen (PSMA), a protein highly expressed in prostate cancer cells. The drug utilizes Syndivia's GeminiMab DAR1 ADC technology to deliver cytotoxic agents directly to PSMA-expressing tumor cells, aiming to maximize anti-tumor efficacy while minimizing off-target toxicity. Preclinical studies have demonstrated a high therapeutic index and substantial safety margin, supporting its advancement into clinical trials. As of April 2025, SDV2102 remains in preclinical development with first-in-human trials anticipated in 2025[1][2][4][5].